Instanosis Wins Prestigious Award for Breakthrough Xylazine Detection Technology
Chicago, IL – July 23, 2025 — Instanosis, a diagnostics company advancing ultra-sensitive drug testing technologies, has been named a recipient of the Academy of Diagnostics & Laboratory Medicine’s Distinguished Abstract Award at the upcoming ADLM 2025 Annual Meeting. The award honors the scientific excellence of Instanosis’s abstract, “A High Sensitivity Rapid Xylazine Dipstick for Clinical Urine Testing.” Selected from over 821 accepted abstracts, the Instanosis submission was one of only 19 recognized by a panel of Academy Fellows, placing it among the top tier of diagnostic research showcased at this year’s global laboratory medicine event.
“This recognition from the Academy affirms the clinical impact and scientific rigor behind our work,” said Dr. Ping Wang, Co-Founder of Instanosis and lead author on the abstract. “Our goal is to deliver frontline diagnostic tools that empower clinicians and communities to respond quickly to emerging drug threats, especially synthetic agents like xylazine that are driving overdose deaths.”
Xylazine, often mixed with opioids such as fentanyl, presents unique clinical and forensic challenges due to its sedative properties and lack of detectability in traditional drug screens. Instanosis’s novel dipstick delivers rapid, point-of-care detection with a sensitivity threshold that addresses an urgent gap in the field.
The winning abstract details the development of this highly specific lateral flow assay and its performance in clinical sample testing, including strong precision and minimal cross-reactivity. In addition to clinical urine samples, the same xylazine dipstick has also been validated by CFSRE in seized drug samples to have 100% concordance with mass spectrometry results.
Award recipients will be formally honored during the Academy Awards Luncheon on July 30 at the ADLM 2025 Annual Meeting in Chicago, IL. Instanosis’s poster presentation will also be recognized on-site with a Distinguished Abstract ribbon and featured in meeting materials.
🗓 Presentation Details
📍 McCormick Place, Room S404c
📅 Tuesday, July 29 | ⏰ 10:30 AM – 12:00 PM CT
🎤 15-minute talk + 3–5 minute Q&A
Instanosis’s technology has been supported by NIH funding and independently validated by institutions such as UCSF, with its InstaStrip Fentanyl test demonstrating 96% sensitivity and specificity in clinical urine samples.